GBG. R. Begieva

G. R. Begieva

*This is an algorithmically generated author record based on publicly available information.

G. R. Begieva has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan within one international nonproprietary name

    by O.G. Pyaterkina, O.A. Karpova, G.R. Begieva, I.I. Zakirov, D.T. Shayapova, C.A. Bagauova

    Background. Due to the widespread use of targeted therapy drugs with various trade names in the treatment of cystic fibrosis, there is a need for a clinical evaluation of the results of treatment with these drugs and their tolerability and safety within the framework of routine clinical practice. Objective. The aim of the study was to present the experience of the Republic of Tatarstan in the etiopathogenetic therapy of ivacaftor + tezacaftor + elexacaftor and ivacaftor with a change of trade name within the same international nonproprietary name in pediatric patients diagnosed with cystic fibrosis, to demonstrate the clinical efficacy of this drug and its safety Conclusion. During 2025, 80 patients received etiopathogenetic therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor, including 12 children under 6 years of age, 19 aged 6 to 12 years, and 46 patients aged 12 to 18 years. The average age of patients at the start of therapy was 7.5 years. Patients with the pulmonary-intestinal form of the disease (E 84.8) prevailed – 78.3%, with a predominantly pulmonary form (E 84.0) – 21.7%. Prior to the initiation of targeted therapy and when changing the drug to a triple fixed dose combination, a comprehensive assessment of the functional capabilities of the child's body was carried out within the framework of one international nonproprietary name. Monitoring of the safety and effectiveness of treatment was carried out 14 days after the start of therapy, 1 month after, 3 months after, 6 months after, and 12 months after. Against the background of the three-component targeted therapy, patients showed an improvement in respiratory function (FEV1 and FVC), positive weight and height dynamics. When changing the drug within the same international nonproprietary name , the indicators of the function of external respiration remained at the achieved level. During the 6 months of follow-up, there were no exacerbations of cystic fibrosis that required hospitalization.


  • Open Access

    Regional experience in monitoring children with cystic fibrosis on targeted therapy in the Republic of Tatarstan

    by O. G. Pyaterkina, O. A. Karpova, G. R. Begieva, I. R. Zinnatullin, I. I. Zakirov

    In connection with the introduction of targeted therapy for cystic fibrosis (CF) into clinical practice, there is a need to study the clinical effectiveness of these drugs and to record their possible side effects in children.The aim was to present the regional experience of the Republic of Tatarstan in the use of etiopathogenetic therapy (ivacaftor + tezacaftor + elexacaftor) in 41 children diagnosed with CF.Methods. Before initiation of triple therapy, a comprehensive assessment of body functions was carried out. Monitoring of safety and effectiveness was carried out at 14 days, 1 month, 3 months, 6 months, and 12 months after from the start of therapy.Results. In the first 2 weeks from the start of therapy, 10 (27%) patients reported mild side effects in the form of increased cough, sputum, and rhinorrhea, 2 (5,4%) patients had skin rashes, and 3 (8,1%) patients had elevated blood aminotransferases. One child developed encephalopathy due to arterial hypertension several months after starting therapy.Conclusion. Monitoring of the safety of the therapy over 12 months in children with CF showed a satisfactory profile. The therapy was associated with an improvement in the body functions, nutritional status, and quality of life.


  • Open Access

    Natural cough remedies: options for a rational choice

    by Kh. M. Vakhitov, O. I. Pikuza, O. A. Karpova, A. M. Kapralova, L. F. Vakhitova, A. V. Ishbuldina, A. M. Zakirova, I. R. Zinatullin, G. R. Shaymardanova, E. Kh. Vakhitov, et al.

    This work summarizes the current understanding of the mechanisms providing mucociliary clearance and their disorders in respiratory diseases. It is noted that currently the understanding of the drainage function of the respiratory tract and cough formation in bronchopulmonary pathology has significantly expanded, and therefore much attention is paid to the search for opportunities to correct these parts of pathogenesis. The use of drugs improving sputum rheology and decreasing inflammatory mucosal edema are of great importance in this aspect. The article summarizes the data on the possibilities of pathogenetic correction of respiratory disorders with the emphasis on the use of expectorants and mucolytic drugs made from herbal raw materials. For many of them a sufficiently rich clinical experience has been accumulated, and modern manufacturing techniques have significantly increased their quality and safety. The mucolytic and expectorant properties of modern herbal remedies are in many cases as good as those of synthetic drugs. An important feature of herbal remedies is that they contain a combination of many components with a complex therapeutic effect, whereby the quality of herbal remedies is ensured by the most modern manufacturing control mechanisms. The paper reflects the main therapeutic effects of herbal remedies, which depend on the plant species and are determined by their content of biologically active substances: alkaloids, glycosides (including anthraglycosides, cardiac glycosides, saponins, flavonoids), phytoncides, essential oils, coumarins, tannins, resins, etc. The results of own observations on the use of herbal remedies in routine clinical practice are presented. The high adherence of patients to the use of herbal syrups and drops based on ivy extract in the therapy of cough syndrome in adults and children is shown.